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London, Ontario, Canada; Durham, North Carolina; and Houston, TexasOBJECTIVES This study tested the diagnostic and prognostic utility of a rapid, visual T1 assessment
method for identiﬁcation of cardiac amyloidosis (CA) in a “real-life” referral population undergoing car-
diac magnetic resonance for suspected CA.
BACKGROUND In patients with conﬁrmed CA, delayed-enhancement cardiac magnetic resonance
(DE-CMR) frequently shows a diffuse, global hyperenhancement (HE) pattern. However, imaging is often
technically challenging, and the prognostic signiﬁcance of diffuse HE is unclear.
METHODS Ninety consecutive patients referred for suspected CA and 64 hypertensive patients with
left ventricular hypertrophy (LVH) were prospectively enrolled and underwent a modiﬁed DE-CMR pro-
tocol. After gadolinium administration a method for rapid, visual T1 assessment was used to identify the
presence of diffuse HE during the scan, allowing immediate optimization of settings for the conventional
DE-CMR that followed. The primary endpoint was all-cause mortality.
RESULTS Among patients with suspected CA, 66% (59 of 90) demonstrated HE, with 81% (48 of 59) of
these meeting pre-speciﬁed visual T1 assessment criteria for diffuse HE. Among hypertensive LVH pa-
tients, 6% (4 of 64) had HE, with none having diffuse HE. During 29 months of follow-up (interquartile
range: 12 to 44 months), there were 50 (56%) deaths in patients with suspected CA and 4 (6%) in patients
with hypertensive LVH. Multivariable analysis demonstrated that the presence of diffuse HE was the most
important predictor of death in the group with suspected CA (hazard ratio: 5.5, 95% conﬁdence interval:
2.7 to 11.0; p < 0.0001) and in the population as a whole (hazard ratio: 6.0, 95% conﬁdence interval 3.0 to
12.1; p < 0.0001). Among 25 patients with myocardial histology obtained during follow-up, the sensi-
tivity, speciﬁcity, and accuracy of diffuse HE in the diagnosis of CA were 93%, 70%, and 84%, respectively.
CONCLUSIONS Among patients suspected of CA, the presence of diffuse HE by visual T1 assess-
ment accurately identiﬁes patients with histologically-proven CA and is a strong predictor of
mortality. (J Am Coll Cardiol Img 2014;7:143–56) ª 2014 by the American College of Cardiology
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CA = cardiac amyloidosis
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CMR = cardiac magnetic
resonance
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enhancement cardiac
magnetic resonance
ECG = electrocardiogram
EMB = endomyocardial bio
HE = hyperenhancement
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LV = left ventricular
LVH = left ventricular
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144he diagnosis of cardiac amyloidosis (CA) METHODS
should be considered in patients with sys-
temic amyloidosis and those with unex-
plained left ventricular hypertrophy (LVH) or
diastolic heart failure. As CA portends poor prog-
nosis (1), its conﬁrmation or exclusion becomes
critical for therapeutic decision-making and patient
counseling. Although consensus guidelines indicate
that invasive endomyocardial biopsy (EMB) is
reasonable in patients with unexplained restrictiveSee page 166cardiomyopathy and suspicion of CA, there are
procedural risks and there is uncertainty about
sampling error (2). Echocardiography is the most
commonly used imaging test in the diagnostic
workup, but characteristic ﬁndings such as ventric-inventors of a
they have no
Manuscript r
ase
psyular hypertrophy and restrictive ﬁlling
pattern are not speciﬁc for CA and may be
insensitive for early disease (3,4).
Recently, several studies have suggested
that delayed-enhancement cardiac mag-
netic resonance (DE-CMR) represents a
promising technique for the diagnosis
of CA (4–9). These investigations report
the high prevalence of a diffuse, global
subendocardial hyperenhancement (HE)
pattern on DE-CMR in patients with
conﬁrmed CA. This pattern is distinctive
and appears speciﬁc to CA, but the diffuse
nature of HE presents challenges for
conventional DE-CMR, as a normal
reference myocardiumdused to provide
context for setting pulse sequence param-
eters and for visual interpretationdmay beabsent. Perhaps in part due to the imaging chal-
lenges, the 3 studies to date that have investigated
the prognostic role of DE-CMR in patients with
CA have yielded inconsistent results (4,8,10);
however, the studies were small and had few events.
The purpose of the current study was to evaluate
the diagnostic and prognostic utility of a rapid, vi-
sual T1 assessment method for identiﬁcation of CA.
In this investigation, we enrolled consecutive pa-
tients referred to cardiac magnetic resonance
(CMR) with suspected (but not known) CA to
prospectively test the practical clinical value of our
new approach in a “real-life” population encoun-
tered during the routine practice of CMR.U.S. patent on Delayed Enhancement CMR, which is owned by
relationships relevant to the contents of this paper to disclose.
eceived September 26, 2013; accepted September 27, 2013.Patient population. STUDY DESIGN. This was a
prospective cohort study that enrolled patients
consecutively referred to the Duke Cardiovascular
Magnetic Resonance Center between March 2003
and July 2007. A total of 154 patients were enrolled:
90 with suspected CA and 64 with hypertensive
LVH. Eleven patients with suspected CA were also
recruited at Nashville Heart Cardiovascular MRI
Center for a pilot phase used to optimize the im-
aging protocol, and 8 normal subjects without his-
tory of cardiac disease were recruited at Duke for
quantitative T1 measurements. All patients signed
informed consent prior to enrollment, and each
institution’s research ethics board approved the
study.
ENROLLMENT. Similar to previous studies (4,7),
patients referred to CMR for suspected CA had at
least 1 of the following: pathology-conﬁrmed sys-
temic amyloidosis (extracardiac tissue biopsy);
conﬁrmed plasma cell dyscrasia; or echocardio-
graphic and/or invasive hemodynamic evidence of a
restrictive cardiomyopathy. Patients with known
CA by EMB at the time of enrollment were
excluded. Hypertensive patients with LVH were
recruited during the same enrollment period; they
were required to have a diastolic wall thickness
$12 mm of either the anteroseptal or posterior wall
on cine-CMR and were excluded for any docu-
mented clinical history of coronary artery disease
(CAD) or cardiomyopathy. Hypertensive patients
with a history of chest discomfort required a normal
stress test or x-ray coronary angiogram (no lesion
$50% of lumen) before enrollment. Some patients
were enrolled before the Food and Drug Adminis-
tration alerts regarding the rare occurrence of
nephrogenic systemic ﬁbrosis associated with gad-
olinium contrast administration (11). None of the
study participants developed nephrogenic systemic
ﬁbrosis during the course of the study.
Cardiac magnetic resonance. IMAGING PROTOCOL.
CMR was performed on 1.5-T scanners (Sonata or
Avanto, Siemens, Erlangen, Germany) using phased-
array receiver coils. Cine images were acquired in
multiple short-axis (every 10 mm throughout the
entire left ventricle) and 3 long-axis views using a
steady-state free-precession sequence (slice thickness
6 mm; interslice gap 4 mm; repetition time (TR)Northwestern University. All other authors have reported that
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1453.0 ms; echo time (TE) 1.5 ms; temporal resolution
35 to 40 ms; ﬂip angle 60; and in-plane resolution
w1.7  1.4 mm).
Delayed-enhancement imaging was performed in
2 distinct ways after gadolinium contrast adminis-
tration (gadoversetamide, 0.15 mmol/kg). First, T1
assessment was performed 5 to 10 min after contrast
using a breath-hold, inversion-recovery cine-SSFP
pulse sequence (5,12,13), in which sequential pha-
ses of the cardiac cycle were acquired at increasing
time from the inversion pulse in 30 ms increments
(starting at 80 ms). Midventricular short-axis and
4-chamber long-axis views were obtained, and T1
assessment was usually completed in 1 to 2min (i.e., 2
breath-holds). Other imaging parameters were: slice
thickness 8 mm; TR 2.2 ms; TE 1.1 ms; ﬂip angle
50; in-plane resolutionw2.5  1.7 mm; and repe-
tition time between inversion pulses: 2 R-R intervals.
The purpose of T1 assessment was to provide an
objective method for the identiﬁcation of diffuse
HE. Following completion of the ﬁrst pass of
gadolinium, normal myocardium will have a
considerably lower concentration of contrast than
blood and, therefore, should have a far longer T1. AFigure 1. Examples of T1 Assessment in a Patient With Hypertensiv
Later Conﬁrmed by Biopsy
Each set of images was acquired in a single breath-hold 5 min after gado
in each frame. In the patient with left ventricular hypertrophy (LVH) (top
beforedthat is, at an earlier IT thandthe myocardium (green square). T
and indicates that after contrast, the T1 of normal myocardium is longer
(bottom), the entire myocardium crosses the null point prior to the bloo
Note that, in isolation, the image with myocardium “nulled” (green squ
the pitfalls of conventional DE-CMR without T1 assessment.shorter (or similar) T1 would indicate abnormal
myocardium with increased gadolinium retention.
To exploit this relationship, we performed a frame-
by-frame visual comparison of myocardial and blood
pool signal over the range of increasing inversion
times to determine relative T1s (Fig. 1). If myocardial
tissue crossed the null point (i.e., became black) at
an earlier or at the same inversion time as blood, the
T1 of that tissue was considered abnormally short.
Similar to that described previously (7), if >50% of
the left ventricular (LV) myocardium on either the
short- or long-axis images had abnormally short T1
in an area that was not in a typical coronary artery
distribution, then diffuseHEwas considered present.
Conventional DE-CMR was then performed
using a segmented inversion-recovery gradient-echo
sequence (slice thickness 6 mm; interslice gap 4 mm;
TR 9.5 ms; TE 3.8 ms; ﬂip angle 25; in-plane
resolution 1.8  1.4 mm) in the identical locations
as cine-CMR (14,15). However, the inversion delay
time was set in a speciﬁc manner. In patients
meeting criteria for diffuse HE, the inversion time
prescribed was that which best demonstrated the
extent of abnormal tissue enhancement by T1e LVH and in a Patient With Suspected Cardiac Amyloidosis
linium administration. The time from the inversion pulse (IT) is shown
), the blood pool reaches the null point (becomes black, red square)
his is the normal relationship in patients without hyperenhancement,
than that of blood. Conversely, in the patient with cardiac amyloidosis
d pool, indicating the presence of diffuse, global hyperenhancement.
are) appears to show that all myocardium is normal, demonstrating
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146assessment. This was the inversion time required to
either null the blood pool (if no normal myocardium
was present) or, if present, normal myocardium. In
patients not demonstrating diffuse HE, the inver-
sion time was prescribed in the conventional fashion
with an aim to null normal myocardium (15).
IMAGE ANALYSIS. Cine and DE-CMR images were
evaluated separately, masked to all patient infor-
mation. Quantitative measurements of LV wall
thickness, mass, volumes, and ejection fraction were
obtained from the stack of short-axis cine images
using standard methods (14). The presence of peri-
cardial and pleural effusions on cine-CMR was
scored in a binary fashion, with trace effusions being
considered normal. DE-CMR images were inter-
preted by consensus of 2 experienced readers (J.A.W.
and H.W.K.); a pre-designated third reader (R.J.K.)
was consulted in cases of interpretive discordance.
The presence of diffuse HE was determined from
T1 assessment as described earlier (Fig. 1). This was
followed by inspection of conventional DE-CMR
images for other (focal) patterns of HE, and these
were scored either as CAD type when they were
subendocardial or transmural in a typical vascular
distribution, or as non-CAD type when they were
midmyocardial or epicardial (16). Intraobserver and
interobserver variability of visual T1 assessment was
tested in 20 patients, 10 of whom were randomly
chosen from the subgroup with diffuse HE and 10
from the subgroup without diffuse HE. Images were
interpreted several months after the initial read. For
both intraobserver and interobserver testing, there
was 100% agreement with the initial read in sepa-
rating patients with and without diffuse HE.
Electrocardiography. Twelve-lead electrocardiograms
(ECGs), obtained a median of 1 day after CMR
(interquartile range [IQR]: 0 to 3 days), were available
in 133 patients overall: 80 (89%) with suspected CA
and 53 (83%) with hypertensive LVH. These were
masked to patient identity and interpreted for lowECG
voltage as described by Rahman et al. (17) (total height
of the QRS complex <5 mm in the limb leads and
<10 mm in the precordial leads), and were assessed for
the presence of Q waves using Minnesota codes 1-1-1
through 1-2-7 [18]).
Echocardiography. Transthoracic echocardiograms,
obtained a median of 1 day prior to CMR (IQR: 4
days before to 2 days after), were available in 99
patients overall: 64 (71%) with suspected CA and
35 (55%) with hypertensive LVH. These were
digitally copied, masked for blinded review, and
analyzed on a commercial workstation (Xcelera,
Philips Medical Systems, Best, the Netherlands).The following were measured as previously
described (19): LV wall thickness (mean of ante-
roseptal and posterior walls), peak early to late
diastolic velocity (E/A) ratio, mitral inﬂow decel-
eration time (DT), and mitral annular septal velocity
(E0). All measurements were made over 3 cardiac
cycles and averaged. Abnormal diastolic function
was classiﬁed according to standard criteria into 3
dysfunctional ﬁlling patterns: slow relaxation,
pseudonormal, or restrictive (19).
Clinical follow-up. Clinical information related to
the occurrence of adverse events was obtained via:
1) telephone interview with the patient or, if
deceased, family members; 2) contact with the pa-
tient’s physician(s); 3) hospital records; and 4) death
certiﬁcates. The pre-speciﬁed primary endpoint was
all-cause mortality. The secondary endpoint was a
composite of death, cardiac transplantation, or hos-
pital admission for heart failure. The latter required
administration of intravenous diuretics for the treat-
ment of pulmonary edema (conﬁrmed by clinical
examination and chest x-ray) or peripheral edema.
For the primary endpoint, all-cause rather than car-
diac mortality was used because the former is objec-
tive, clinically relevant, and unbiased, which is often
not the case for cardiac mortality (20). Cardiac
troponin T levels, if measured, were also recorded.
Myocardial histopathology. All cardiac tissue ob-
tained during the follow-up period from endo-
myocardial biopsy, cardiac transplantation, or
autopsy were evaluated in a systematic manner.
Samples were examined by light microscopy,
immunoﬂuorescence, and electron microscopy.
Amyloid protein was considered present upon
demonstration of apple-green birefringence under
polarized light or the appearance of amyloid ﬁbrils
on electron microscopy (21). Immunohistochemical
stains using commercially-available antisera to
kappa and lambda immunoglobulin light chains
were also employed (21,22).
Statistical analysis. Continuous data were expressed
as mean  SD, or in cases in which the distribu-
tion was not normal, as median and interquartile
range. Comparisons of continuous data between
groups were made using 2-sample t test or the
Wilcoxon rank sum test as appropriate. The
chi-square test was used to make between-group
comparisons of discrete data. To identify variables
associated with adverse outcome, univariable
Cox proportional hazards regression analysis was
performed. Multivariable models were subsequently
developed using 2 approaches. In the ﬁrst, candidate
variables showing a possible association with prog-
nosis by univariable analysis (p < 0.05) were
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147considered 1 at a time starting with the most sig-
niﬁcant candidate. Final model variables were
determined by stepwise selection (and backwards
elimination) at the level of signiﬁcance of p ¼ 0.05.
In the second approach, only 4 variables were
included to avoid the potential for overﬁtting. These
were 3 well-known clinical markers of prognosis in
cardiac amyloidosisdLV ejection fraction, ECG
low-voltage pattern, and LV mass (23)dand HE.
For both approaches, 2 submodels were con-
structed, 1 including “diffuse” HE and the other
including “any” HE. Results were presented as
hazard ratios (HRs) and their associated 95%
conﬁdence intervals (CIs) for the model variables,
as well as likelihood ratios for the models. Cumu-
lative event rates were calculated according to the
Kaplan-Meier method. Comparisons between sur-
vival curves were made using Cox regression anal-
ysis after adjusting for other signiﬁcant covariates
from the multivariable models. All statistical tests
were 2-tailed, and p < 0.05 was regarded as sig-
niﬁcant. S-Plus (version 8.0, Insightful Software,
Seattle, Washington) was used to perform the
statistical analyses.
RESULTS
Patient characteristics. Among patients with sus-
pected CA, 46 (51%) had documented systemic
(extracardiac) amyloidosis at the time of enrollment:
41 had monoclonal light chain amyloid, 2 had
secondary amyloid, and 3 had hereditary amyloid (2
with variant transthyretin, 1 with variant ﬁbrin-
ogen). Of the remaining 44 patients with suspected
CA, 16 had a diagnosis of plasma cell dyscrasia and
28 had echocardiographic and/or invasive hemody-
namic evidence of restrictive cardiomyopathy.
Baseline characteristics are shown in Table 1 for
patients with suspected CA in comparison with
those with hypertensive LVH. Patients with sus-
pected CA were slightly older, had worse New York
Heart Association (NYHA) functional class, more
often had signs of right heart failure (peripheral
edema and/or ascites in the presence of an elevated
jugular venous pressure), and were more likely to
have low voltage on ECG. Patients with suspected
CA also had higher E/A ratios, had shorter decel-
eration times, and were more likely to have pseudo-
normal or restrictive diastology on echocardiography.
On cine-CMR, there were no signiﬁcant differences
in LV mass index or LV end-diastolic volume index,
but there was a mild increase in LV end-systolic
volume index, leading to a comparative decrease in
LV ejection fraction (median 56% vs. 69%). Therewas also a higher prevalence of pericardial (50% vs.
14%) and pleural effusions (48% vs. 9%) in the group
with suspected CA.
DE-CMR ﬁndings. Figure 2 summarizes the DE-
CMR ﬁndings in the 2 cohorts. Among patients
with suspected CA, 59 (66%) demonstrated HE,
81% (48 of 59) of whom met visual T1 assessment
criteria for diffuse HE. Focal CAD-type HE was
observed in 11 patients, 6 of whom also had diffuse
HE. Focal non–CAD-type (midwall or epicardial)
HE was noted in 6 patients, none of whom had
diffuse HE concurrently. Among hypertensive
LVH patients, 4 (6%) had HE, and none were
diffuse. Findings in the subgroup of 46 patients
with documented systemic (extracardiac) amyloid-
osis at the time of enrollment are also shown in
Figure 2. A total of 34 patients (74%) had HE, 85%
(29 of 34) of whom had diffuse HE. Typical CMR
images of patients with diffuse HE are shown in
Figure 3.
The mean difference in inversion times corre-
sponding to the frames where blood and myocardial
signals were nulled was 50  30 ms (range
0 to þ125 ms) for patients with diffuse HE
and 72  25 ms (range 110 to 43 ms) for
hypertensive LVH patients (p < 0.0001). Blood T1
was estimated based on the inversion time (IT) to
null blood (T1 ¼ [1/ln(2)] x IT[null]) and found to
be 313  70 ms in patients with diffuse HE and
285  68 ms in hypertensive patients. In 8 normal
subjects without history of cardiac disease, T1
assessment was performed until 30 min post-
contrast to test if T1 of normal myocardium may
become shorter than that of blood within a
clinically-relevant time period. In all 8 patients, the
T1 of normal myocardium remained longer than
that of blood, with a mean difference of 76  30 ms
(range 36 to 119 ms) at 30 min.
Survival. ENTIRE POPULATION. The median follow-
up time was 29 months (IQR: 12 to 44 months). No
patient was lost to follow-up. During this period
there were 50 (56%) deaths in patients with sus-
pected CA and 4 (6%) deaths in patients with hy-
pertensive LVH (p < 0.0001). The relationships
between clinical and CMR characteristics with the
primary endpoint of all-cause mortality are shown in
Table 2. Among the characteristics that were
signiﬁcantly associated with mortality, “diffuse” and
“any” HE were the strongest univariable predic-
tors (highest t statistic). For multivariable analysis,
separate submodels were constructed, 1 including
“diffuse” HE and the other including “any” HE.
Table 2 demonstrates that NYHA functional class,
serum creatinine, the presence of pleural effusion,
Table 1. Baseline Patient Characteristics
Suspected CA
(n [ 90)
Hypertensive LVH
(n [ 64) p Value
Age, yrs 62  13 57  13 0.01
Male 52 (58) 46 (72) 0.07
NYHA functional class 3.0 (1.0, 3.0) 1.0 (1.0, 2.0) <0.0001
Right heart failure 54 (60) 5 (8) <0.0001
Dialysis 13 (14) 1 (2) 0.01
Systolic blood pressure, mm Hg 120.9  23.4 148.2  26.0 <0.0001
Diastolic blood pressure, mm Hg 71.6  11.9 86.4  15.1 <0.0001
Serum creatinine, mg/dl 1.2 (1.0, 2.3) 1.1 (1.0, 1.4) 0.06
Electrocardiography*
Low voltagey 50 (63) 9 (17) <0.0001
Q wavez 6 (8) 3 (6) 0.68
Echocardiographyx
Mean LV wall thickness, mm 14.2  3.2 14.0  3.2 0.72
E/A ratio 2.1 (1.1, 2.9) 1.0 (0.8, 1.5) <0.0001
Deceleration time, ms 156 (124, 188) 200 (172, 236) <0.0001
Deceleration time <160 ms 35 (55) 6 (17) 0.0003
E/E’ ratio 19.4 (14.3, 28.6) 17.8 (10.3, 28.3) 0.39
E/E’ ratio >15 45 (71) 20 (56) 0.17
Pseudonormal or restrictive diastology 41 (65) 11 (31) 0.002
Cine-CMR
Mean LV wall thickness, mm 12.8  3.8 12.5  3.4 0.63
LV mass index, g/m2 91 (69, 126) 83 (69, 107) 0.21
LV EDV index, ml/m2 58 (43, 76) 66 (53, 77) 0.09
LV ESV index, ml/m2 24 (18, 36) 22 (13, 30) 0.04
LV ejection fraction, % 56 (47, 65) 69 (61, 73) <0.0001
Pericardial effusion 45 (50) 9 (14) <0.0001
Pleural effusion 43 (48) 6 (9) <0.0001
DE-CMR
Any HE 59 (66) 4 (6) <0.0001
Diffuse HE 48 (53) 0 (0) <0.0001
CAD-type HE 11 (12) 2 (3) 0.05
Focal non-CAD-type HE (midwall or epicardial) 6 (7) 2 (3) 0.47
Values are mean  SD, n (%), or median (25th, 75th percentile). Numbers in boldface indicate p values #0.05. *Available in 133 patients, 80 with suspected CA and
53 with hypertensive LVH; ydeﬁned as total height of the QRS complex <5 mm in the limb leads and <10 mm in the precordial leads; zdeﬁned by Minnesota codes
1-1-1 through 1-2-7; xavailable in 99 patients, 64 with suspected CA and 35 with hypertensive LVH.
CA¼ cardiac amyloidosis; CAD¼ coronary artery disease; CMR¼ cardiac magnetic resonance; DE¼ delayed-enhancement; E/A¼ peak early to late diastolic velocity;
EDV ¼ end-diastolic volume; ESV ¼ end-systolic volume; HE ¼ hyperenhancement; LV ¼ left ventricular; LVH ¼ left ventricular hypertrophy; NYHA ¼ New York Heart
Association.
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148and the respective HE variable were independent
predictors of mortality in both submodels. For sub-
model 1, diffuse HE was the strongest predictor
(highest t statistic), with an HR of 6.0 (95% CI: 3.0
to 12.1; p < 0.0001). For submodel 2, any HE was
the strongest predictor, with an HR of 6.5 (95% CI:
3.0 to 14.2; p < 0.0001). Overall, the 2 submodels
had similar predictive capabilities, with chi-square
values of 100.2 and 99.7, respectively.Concerning the secondary endpoint, there were
54 (56%) patients with suspected CA and 8 (13%)
with hypertensive LVH who experienced death,
cardiac transplantation, or hospital admission for
heart failure during follow-up. Results from multi-
variable analyses were similar to that for the primary
endpoint in that diffuse HE was the strongest
predictor in submodel 1 (HR: 5.8, 95% CI: 3.2 to
10.5; p < 0.0001) and any HE was the strongest
Total Population
(N=154)
Hypertensive LVH
(N=64)
HE
N=4
N=4N=0
Diffuse
N=60
+ -
+ -
Suspected Cardiac Amyloid
(N=90)
HE
N=59
N=11N=48
Diffuse
N=31
+ -
+ -
Sub-group with Documented
Extra-cardiac Amyloid
(N=46)
HE
N=34
N=5N=29
Diffuse
N=12
+ -
+ -
Figure 2. Diagram Showing the Prevalence of any HE and “Diffuse” Global HE Among Patients With Hypertensive LVH
and Suspected Cardiac Amyloidosis
Findings in the subgroup with documented extracardiac amyloidosis are also shown. HE ¼ hyperenhancement; LVH ¼ left ventricular
hypertrophy.
Figure 3. Typical Findings in 3 Patient Examples
(A) Four-chamber cine cardiac magnetic resonance (CMR) and delayed-enhancement
cardiac magnetic resonance (DE-CMR) images in a 52-year-old man with systemic primary
amyloidosis 5 months prior to his death. Diffuse, primarily subendocardial
hyperenhancement is seen in both the left and right ventricles as well as in the interatrial
septum. (B) A 61-year-old man with myeloma and new-onset heart failure showing diffuse
subendocardial hyperenhancement. Patient died 6 months later. (C) A 49-year-old woman
with restrictive cardiomyopathy by echocardiography and invasive hemodynamics showing
diffuse hyperenhancement of the left ventricle. Patient died 45 days later.
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149predictor in submodel 2 (HR: 6.2, 95% CI: 3.1 to
12.3; p < 0.0001). Again, the 2 submodels had
similar overall predictive capability, with chi-square
values of 103.1 and 101.6, respectively.
PATIENTS WITH SUSPECTED CA. Survival analyses
were repeated with the removal of patients with
hypertensive LVH. Results were similar to that for
the whole population. For the primary endpoint,
diffuse HE was the strongest predictor in submodel
1 (HR: 5.5, 95% CI: 2.7 to 11.0; p < 0.0001) and
any HE the strongest predictor in submodel 2 (HR:
7.9, 95% CI: 3.1 to 20.1; p < 0.0001). For both
submodels, the other independent predictors were
serum creatinine and the presence of pleural effu-
sion. For the secondary endpoint, diffuse HE (HR:
4.7, 95% CI: 2.4 to 9.4; p < 0.0001) or any HE
(HR: 6.5, 95% CI: 2.6 to 16.0; p < 0.0001) was
the strongest predictor in the multivariable models.
Kaplan-Meier survival curves according to any or
diffuse HE and primary or secondary endpoint are
shown in Figure 4. Survival curves were adjusted for
baseline differences in covariates (serum creatinine
and presence of pleural effusion) found to inde-
pendently predict outcome. In each case, the pres-
ence of HE (any or diffuse) was associated with a
marked reduction in survival (all p < 0.0001). For
instance, patients with diffuse HE had a 2-year
survival rate of only 21% in comparison to 81% in
those without HE. When survival analysis was per-
formed after removal of patients with hereditaryamyloidosis, there were no signiﬁcant changes in
the ﬁndings in that: 1) the same independent pre-
dictors were found for both submodels 1 and 2;
Table 2. Predictors of Mortality in All Patients
Univariable
Multivariable Model
Using Diffuse HE
Multivariable Model
Using Any HE
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
All (n ¼ 154)
Clinical
Age, yrs 1.03 (1.01–1.05) 0.02
Male 0.8 (0.4–1.3) 0.32
NYHA functional class 2.4 (1.8–3.1) <0.0001 1.4 (1.0–1.9) 0.03 1.5 (1.1–2.0) 0.01
Right heart failure 5.4 (3.0–9.5) <0.0001
Dialysis 4.3 (2.2–6.9) <0.0001
Systolic blood pressure, mm Hg 0.97 (0.96–0.98) <0.0001
Diastolic blood pressure, mm Hg 0.96 (0.94–0.99) 0.0004
Serum creatinine, mg/dl 1.3 (1.2–1.5) <0.0001 1.3 (1.2–1.5) <0.0001 1.3 (1.1–1.4) 0.0001
Elevated troponin-T 5.1 (2.6–10.2) <0.0001
Electrocardiography
Low voltage 3.6 (2.0–6.6) <0.0001
Q wave 0.8 (0.4–1.4) 0.44
Cine-CMR
Mean LV wall thickness, mm 5.2 (2.6–10.6) <0.0001
LV mass index, g/m2 1.02 (1.01–1.02) <0.0001
LV EDV index, ml/m2 0.988 (0.975–1.002) 0.09
LV ESV index, ml/m 1.009 (0.998–1.020) 0.11
LV ejection fraction, % 0.97 (0.95–0.98) <0.0001
Pericardial effusion 2.5 (1.5–4.3) 0.0009
Pleural effusion 4.9 (2.9–8.5) <0.0001 2.6 (1.4–4.6) 0.002 3.1 (1.7–5.5) 0.0002
DE-CMR
Any HE 12.8 (6.2–26.5) <0.0001 6.5 (3.0–14.2) <0.0001
Diffuse HE 12.0 (6.5–22.1) <0.0001 6.0 (3.0–12.1) <0.0001
CAD-type HE 3.6 (1.8–7.2) 0.0003
Focal non-CAD-type HE 0.6 (0.2–2.6) 0.52
Model chi-square test 100.2 <0.0001 99.7 <0.0001
Continued on the next page
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1502) the HRs were nearly identical; and 3) diffuse HE
(HR: 5.5, 95% CI: 2.6 to 11.4; p < 0.0001) or any
HE (HR: 8.8, 95% CI: 3.1 to 24.9; p < 0.0001)
were the most signiﬁcant independent predictors of
all-cause mortality.
In a separate multivariable modeling approach,
only 4 variables were included to avoid the potential
for overﬁtting. Three were pre-selected on the basis
that they were well-known clinical markers of
prognosis in cardiac amyloidosisdLV ejection
fraction, ECG low-voltage pattern, and LV mass
(23)dand the fourth was HE by CMR. With this
approach (Table 3), diffuse HE was again the
strongest predictor of mortality in submodel 1 (HR:
4.95, 95% CI: 2.12 to 11.6; p ¼ 0.0002) and anyHE was the strongest predictor in submodel 2 (HR:
9.25, 95% CI: 2.98 to 28.7; p ¼ 0.0001).
PATIENTS WITH SYSTEMIC (EXTRACARDIAC)
AMYLOIDOSIS. Among the subcohort of 46 patients
that had documented systemic amyloidosis at the time
of enrollment, 7 eventually underwent intravenous
chemotherapy (melphalan) followed by stem cell
transplantation and 5 received oral chemothe-
rapy. There was no association between treatment
regimen (stem cell transplantation, oral chemothe-
rapy, or either treatment) and survival (all p > 0.20).
Multivariable analysis demonstrated that diffuse
HE (HR: 3.6, 95% CI: 1.4 to 9.5, p ¼ 0.009) or any
HE (HR: 6.1, 95% CI: 1.7 to 22.5, p ¼ 0.006) were
Table 2. Continued
Univariable
Multivariable Model
Using Diffuse HE
Multivariable Model
Using Any HE
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Echocardiography subgroup (n ¼ 99)
Echo parameters
Mean LV wall thickness, mm 2.1 (0.9–5.3) 0.10
E/A ratio 1.5 (1.2–1.8) <0.0001
Deceleration time, ms 0.94 (0.99–1.00) 0.05
Deceleration time <160 ms 2.1 (1.1–3.7) 0.02
E/E’ ratio 1.04 (1.01–1.07) 0.003
E/E’ ratio >15 2.1 (0.9–4.7) 0.07
Pseudonormal or restrictive diastology 1.6 (1.3–2.0) <0.0001 1.4 (1.1–1.8) 0.004
Clinical
Age, yrs 1.02 (1.00–1.05) 0.07
Male 0.7 (0.4–1.2) 0.17
NYHA functional class 2.0 (1.5–2.6) <0.0001 1.4 (1.0–2.0) 0.04
Right heart failure 3.5 (1.8–6.8) 0.0002
Dialysis 3.3 (1.6–6.8) 0.001
Systolic blood pressure, mm Hg 0.98 (0.96–0.99) 0.0005
Diastolic blood pressure, mm Hg 0.97 (0.95–0.99) 0.006
Serum creatinine, mg/dl 1.2 (1.1–1.4) 0.0003 1.3 (1.1–1.5) 0.0002 1.3 (1.1–1.5) 0.0002
Elevated troponin-T 3.6 (1.7–7.5) 0.0007
Electrocardiography
Low voltage 2.7 (1.4–5.2) 0.003
Q wave 1.0 (0.5–1.8) 0.90
Cine-CMR
Mean LV wall thickness, mm 3.2 (1.5–6.9) 0.003
LV mass index, g/m2 1.01 (1.01–1.02) 0.004
LV EDV index, ml/m2 0.986 (0.971–1.000) 0.051
LV ESV index, ml/m2 1.002 (0.990–1.014) 0.79
LV ejection fraction, % 0.98 (0.96–0.99) 0.008
Pericardial effusion 1.9 (1.0–3.4) 0.04
Pleural effusion 3.1 (1.7–5.7) 0.0002 2.0 (1.1–4.0) 0.04 2.5 (1.3–4.7) 0.008
DE-CMR
Any HE 7.9 (3.5–17.9) <0.0001 4.3 (1.8–10.3) 0.001
Diffuse HE 8.1 (4.1–16.0) <0.0001 4.1 (1.8–9.2) 0.0007
CAD-type HE 2.0 (0.9–4.4) 0.11
Focal non-CAD-type HE 0.5 (0.1–2.1) 0.35
Model chi-square test 58.4 <0.0001 56.8 <0.0001
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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151independent predictors of all-cause mortality. Pati-
ents with diffuse HE had a 2-year survival rate of only
23% in comparison with 75% in those without HE.
PATIENTS WITH ECHOCARDIOGRAPHY. Among
the subcohort of 99 patients with echocardiographydata, multivariable analysis showed nearly the same
ﬁndings as in the whole population, suggesting that
the echocardiography subcohort was representative
of the entire group. For instance, in submodel
1, the same 4 variables (NYHA functional class,
serum creatinine, presence of pleural effusion, and
Figure 4. Kaplan-Meier Survival Curves for Patients With Suspected Cardiac Amyloidosis
The relationships between the presence of “any” or “diffuse” hyperenhancement (HE) and the primary endpoint of all-cause mortality are
shown in A and B, respectively. The relationships between HE and the secondary endpoint of death, cardiac transplantation, or admission for
heart failure (HF) are shown in C and D. The number at risk are shown for plots concerning diffuse HE. Survival curves were adjusted for
baseline differences in covariates (serum creatinine and presence of pleural effusion) found to independently predict outcome. In all cases, the
presence of HE was associated with signiﬁcantly worse outcome.
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152diffuse HE) were found to be independent pre-
dictors of all-cause mortality in the echocardiog-
raphy subcohort (Table 2, bottom) as in the entire
population. Although univariable analysis revealed
that several echocardiographic parameters were
associated with all-cause mortality, only the pres-
ence of a pseudonormal or restrictive ﬁlling pat-
tern was found to be an independent predictor,
and only in submodel 2 incorporating “any HE”
(Table 2).
Cardiac histopathology. During follow-up, myocar-
dial tissue samples were obtained in 25 (28%) pa-
tients with suspected CA: 19 by EMB, 2 at time of
cardiac transplantation, and 4 by post-mortem nec-
ropsy examination. Samples from 15 (60%) patients
were positive for cardiac amyloid and demons-
trated at least moderate interstitial amyloid protein
deposition, frequently with perivascular inﬁltration.
Varying degrees of myocyte loss and ﬁbrosis were also
observed, ranging from mild to severe. Of the 10
subjects found to be negative for cardiac amyloid,
5 demonstrated nonspeciﬁc patchy ﬁbrosis, 1 re-
vealed myocarditis, and 4 were normal.All 15 patients with pathological evidence of CA
demonstrated HE on DE-CMR. Of these, 14
(93%) had diffuse HE and 1 had focal sub-
endocardial (CAD-type) HE. An example of the
correlation between pathology and CMR is shown
in Figure 5. Of the 10 patients without pathological
evidence of CA, 7 had normal DE-CMR with no
HE and 3 met criteria for diffuse HE. For all
3 latter patients, tissue samples were obtained by
EMB, and DE-CMR demonstrated a relative
sparing of HE along the right ventricular side of the
interventricular septum, suggesting the potential for
tissue sampling error. All 3 patients subsequently
died but did not have autopsy performed. Overall,
among the patients with myocardial histology, the
sensitivity, speciﬁcity, and accuracy of diffuse HE
in the diagnosis of CA was 93%, 70%, and 84%,
respectively.
D I SCUSS ION
In this study, we tested the utility of a modiﬁed DE-
CMR protocol to provide diagnostic and prognostic
Table 3. Multivariable Models With Pre-Selected Variables in Patients With Suspected Cardiac Amyloidosis
Suspected CA (n [ 90)
Multivariable Model Using
Diffuse HE
Multivariable Model Using
Any HE
HR (95% CI) p Value HR (95% CI) p Value
Non–DE-CMR variables
LV ejection fraction, % 1.00 (0.98–1.02) 0.93 0.99 (0.98–1.01) 0.92
LV mass index, g/m2 1.01 (0.99–1.01) 0.49 1.00 (0.99–1.00) 0.97
ECG low voltage 1.03 (0.51–2.08) 0.94 1.24 (0.64–2.40) 0.53
DE-CMR
Any HE d 9.25 (2.98–28.7) 0.0001
Diffuse HE 4.95 (2.12–11.6) 0.0002 d
Model chi-square test 28.9 <0.0001 34.0 <0.0001
ECG ¼ electrocardiogram; other abbreviations as in Table 1.
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153information in patients referred for suspected cardiac
amyloidosis. Although several investigations have
described a characteristic pattern on conventional
DE-CMRddiffuse global subendocardial HE with
variable epicardial extension (4–9)dit is commonly
reported that imaging is difﬁcult and that quality is
often suboptimal (5–7,9,24). This is because con-
ventional DE-CMR relies on correctly setting an
imaging parameter (inversion time) to null signalFigure 5. Pathology Correlation in a Patient With Primary Amyloid
Gross morphology (top left) shows globally-increased wall thickness o
cine cardiac magnetic resonance (top right). Tissue from the intervent
amyloid deposition, with apple-green birefringence under polarized lig
delayed-enhancement cardiac magnetic resonance, which was particulfrom “normal” myocardium, yet normal myocardium
may be absent in CA.
We used a T1 assessment sequence similar to that
employed by Maceira et al. (5) But, rather than
quantitatively calculating T1 ofﬂine in an effort to
examine gadolinium kinetics, our goal was to pro-
spectively test a practical approach to acquiring and
interpreting the images in a “real-life” referral pop-
ulation. Our visual T1 assessment approach wasosis
f both the left and right ventricles, as also demonstrated in vivo by
ricular septum stained with Congo red shows marked interstitial
ht (bottom left) correlating with diffuse hyperenhancement on
arly evident in the septum (bottom right).
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portional to the inversion time needed to null signal
(T1z [IT(null)]/ln[2]), and that following contrast
administration, blood T1 is far shorter than that of
normal myocardium (25). Thus, simply identifying
that myocardial tissue reaches the null crossing
(becomes black) at an earlier or the same inversion
time as blood pool establishes that this tissue is
abnormal (Fig. 1).
Although sophisticated evaluation of absolute T1
values are of growing interest (26), we suggest that
a binary visual threshold approach, as validated in
this study, provides certain advantages in the
context of this disease state. The method is quick
because the assessment is visual and performed
without ofﬂine analysis; yet, it is objective because
the threshold for dichotomizing normal from
abnormal is unambiguous. Importantly, from a
practical, hands-on perspective, the speed of the
visual T1 assessment approach allows the ﬁndings
to inﬂuence the scan itself by providing optimal
settings for conventional DE-CMR, which imme-
diately follows. For instance, if myocardium was
globally abnormal on visual T1 assessment, then
the inversion time for DE-CMR should be set to
null blood pool rather than myocardium and images
would accurately demonstrate global myocardial
HE (Fig. 1, bottom, red frame), whereas if
myocardium was erroneously nulled (Fig. 1, bot-
tom, green frame), all regions may appear normal,
highlighting the pitfalls of conventional DE-CMR
without T1 assessment. The current study is the
ﬁrst to suggest that, in the presence of diffuse CA,
the appropriate inversion time for conventional
DE-CMR may be that needed to null the blood
pool rather than myocardium.
With this approach, diffuse HE was observed in
48 of 90 patients with suspected CA, and among
the subgroup with cardiac pathology validation (n ¼
25), the sensitivity and speciﬁcity of diffuse HE in
the diagnosis of CA were 93% and 70%, respec-
tively. Results were similar to that of earlier studies
(4,7), although visual T1 assessment appeared to
have higher sensitivity with lower speciﬁcity. For
instance, Vogelsberg et al. (7), in an investigation of
33 patients referred for suspected CA, reported a
sensitivity and speciﬁcity of 80% and 94%, respec-
tively, for the detection of CA by DE-CMR in
comparison with endomyocardial biopsy. Two is-
sues should be considered, however, regarding the
moderate speciﬁcity found in our study. First, unlike
the report by Vogelsberg et al. (7), cardiac biopsy
was not guided by the location of abnormalities on
CMR and the LV free wall was not sampled. It istherefore possible that random biopsy of the right
ventricular side of the interventricular septum (as in
our study) may result in less accurate sampling of
diseased myocardium and a higher “false-positive”
rate for DE-CMR (27). This possibility is consis-
tent with the ﬁnding that all 3 patients with diffuse
HE and negative biopsy demonstrated relative
sparing of HE along the right ventricular border of
the interventricular septum. Second, it is notable
that none of the 64 patients with hypertensive LVH
had diffuse HE despite similar LV hypertrophy
(mass) to patients with suspected CA. Thus, it ap-
pears that diffuse HE on visual T1 assessment is
rare in cohorts with little to no risk of CA, and if
patients with hypertensive LVH had been included
in the analysis as true negatives, speciﬁcity would
have increased to 96% (71 of 74), with sensitivity
unchanged at 93%.
The principal ﬁnding in this cohort study was that
the presence of diffuse HE by visual T1 assessment
was a strong predictor of mortality, with an HR of
6.0 (95% CI: 3.0 to 12.1) on multivariable analysis.
Three prior studies have aimed to evaluate the
prognostic role of DE-CMR in patients with known
or suspected CA and have reported conﬂicting re-
sults. The ﬁrst, by Maceira et al. (10), followed 29
patients with known CA over a period of approxi-
mately 21 months. Given the small number of pa-
tients, multivariable analysis was not performed, and
the presence of diffuse DE seen in 20 patients (69%)
was not predictive of death. A post-hoc analysis of
gadolinium kinetics, however, suggested that
reduced differences in intramyocardial T1 (epicardial
versus endocardial T1 at 2 min after contrast
administration) was associated with increased mor-
tality. Ruberg et al. (8), reported on 28 patients with
systemic, light-chain amyloidosis in whom cardiac
involvement was suspected. Although the presence
of HE did not predict survival, there were only 5
deaths over a median follow-up period of 29 months.
Austin et al. (4), retrospectively reviewed 47 patients
with systemic amyloidosis and suspected CA or
suspected restrictive cardiomyopathy who had un-
dergone clinical CMR. In that study, the presence of
diffuse HE by DE-CMR was predictive of prog-
nosis; indeed, of multiple clinical characteristics
including detailed noninvasive testing, diffuse HE
was the sole predictive variable. However, events
were few, with only 9 deaths during the 1-year
follow-up period. In comparison to these earlier
investigations, our study was substantially larger, and
during a median follow-up period of approximately
2.5 years there were 54 deathsdfar more than the
31 deaths in the 3 earlier studies combined.
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155Given that the value of any prognostic marker may
change depending on the cohort studied, we per-
formed multivariable analyses not only in the popu-
lation as a whole, but also in several subgroups. The
presence of diffuse HE was a strong independent
predictor of mortality in: 1) the entire population
(patients with suspected CA or hypertensive LVH,
n ¼ 154); 2) patients with echocardiography data
(n ¼ 99); 3) patients with suspected CA (n ¼ 90);
and 4) patients with documented systemic amyloid-
osis at the time of enrollment (n ¼ 46). The HRs
were similar among the 4 cohorts, indicating that
diffuse HE identiﬁed by visual T1 assessment is a
robust marker of outcome and suggesting its prog-
nostic utility in a variety of referral populations.
Additionally, it appears that the ﬁnding of focal,
nondiffuse HE should not be disregarded, because
the presence of “any HE” was also a strong inde-
pendent predictor of mortality in the same 4 cohorts.
Study limitations. In an effort to keep the scan
protocol short and clinically relevant, visual T1
assessment was performed using only 2 views
(midventricular short-axis and 4-chamber long-axis
planes). Additionally, the purpose of visual T1
assessment was to detect diffuse, global HE rather
than all regions with focal HE; nonetheless, it is
possible that additional views, such as a complete
short-axis stack of images, could result in improved
sensitivity for detecting CA compared with that
found in the current study. We did not examine
gadolinium kinetics, which may provide insight into
the mechanism of diffuse HE in cardiac amyloid-
osis. However, as mentioned earlier, the primary
goal of our study was to prospectively test a practical
visual approach to performing and interpreting DE-
CMR in the setting of diffuse, global myocardial
disease. Only 1 dose of contrast (0.15 mmol/kg)
with a clinically-convenient time window for T1
assessment (i.e., 5 to 10 min after contrast) was
investigated. There should be caution in applying
this method at different contrast doses and/or time
windows. Our study was not designed to provide asystematic comparison with other biomarkers and
imaging techniques known to have prognostic value
in cardiac amyloidosis, such as B-type natriuretic
peptide and strain Doppler imaging (21,28–30).
Although a recent study reported superiority of DE-
CMR compared with a battery of noninvasive tests
commonly performed in patients with suspected CA
(4), additional studies are clearly necessary to
determine the clinical role of DE-CMR with or
without visual T1 assessment in patients with sus-
pected CA. The number of patients receiving
pathological evaluation of the myocardium was
relatively modest and therefore limits the evaluation
of diagnostic accuracy for visual T1 assessment. A
larger study with focus on histopathological valida-
tion is therefore desirable. Some patients were
enrolled prior to Food and Drug Association
warnings of nephrogenic systemic ﬁbrosis in pa-
tients with severe renal insufﬁciency (glomerular
ﬁltration rate <30 ml/min/1.73 m2) (11). None of
the study participants were diagnosed with neph-
rogenic systemic ﬁbrosis during follow-up; however,
the use of DE-CMR will be limited in patients with
signiﬁcant renal impairment.
CONCLUS IONS
A modiﬁed DE-CMR protocol with visual T1
assessment was tested and shown to accurately iden-
tify patientswithmyocardial amyloid tissue deposition
and those at a markedly increased risk of death.
Overall, this suggests strong diagnostic and progno-
stic utility for the proposed DE-CMR protocol in
patients referred for suspected cardiac amyloidosis.
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